RxDoctor Payments Data

Lydia Shajenko, MD

Clinical Neurophysiology · Edgewater, NJNPI 1841289634

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $64,525 of the $84,722 with a category attached, or 76.2%. AbbVie accounts for 83.7% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2021 at $26,805 and has fallen 95.4% since, to $1,239 in 2025.

$84,722in general payments, 2019–2025

Across 1,272 payments — averaging $66.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$71K
  • Livanova USA, Inc.$2K
  • Pfizer$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Scilex Pharmaceuticals Inc.$1K
  • Amgen$904
  • plus $8K from 54 others

What the payments were for

  • Speaking & faculty fees$64,52576%
  • Travel & lodging$2,6133%
  • Food & beverage$17,39621%
  • Education$1880%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)464$70,880
Livanova USA, Inc.16$1,661
Pfizer97$1,084
Teva Pharmaceuticals USA, Inc.52$1,057
Scilex Pharmaceuticals Inc.93$1,037
Amgen(2 entities)65$904
Biohaven Pharmaceutical Holding Company Ltd.40$729
Lilly USA, LLC47$716
Pacira Pharmaceuticals Incorporated11$657
Lundbeck LLC40$618
Corium, LLC22$353
Biogen20$271
Sanofi12$262
Neurelis, Inc.9$243
Avanir Pharmaceuticals, Inc.16$219
SK Life Science, Inc.14$214
Biohaven Pharmaceuticals, Inc.24$202
Argenx US, Inc.6$199
Novartis18$183
CSL Behring10$177
Neurocrine Biosciences, Inc.12$177
Axsome Therapeutics, Inc.10$170
Impel Pharmaceuticals Inc.13$157
Adamas Pharmaceuticals, Inc.11$146
Collegium Pharmaceutical, Inc.10$144
Sunovion Pharmaceuticals Inc.7$140
Azurity Pharmaceuticals, Inc.9$134
Bristol Myers Squibb8$122
UCB, Inc.8$118
Medtronic2$117
Upsher-smith Laboratories LLC8$114
GE HealthCare8$108
Almatica Pharma LLC7$94
Arbor Pharmaceuticals, Inc.7$92
Acadia Pharmaceuticals Inc6$90
Eisai Inc.6$85
Supernus Pharmaceuticals, Inc.6$83
AstraZeneca6$79
Life Molecular Imaging Ltd4$74
Nevro Corp.1$72
Daiichi Sankyo Inc.5$68
Zyla Life Sciences, Inc.4$59
Harmony Biosciences LLC4$58
E.r. Squibb & Sons, L.L.C.4$54
Merz Pharmaceuticals, LLC3$53
MDD US Operations, LLC3$53
Ipsen Biopharmaceuticals, Inc3$49
Takeda Pharmaceuticals U.S.A., Inc.2$44
Bausch Health US, LLC3$40
Otsuka America Pharmaceutical, Inc.2$33
Grifols USA, LLC1$31
Currax Pharmaceuticals LLC2$31
Johnson & Johnson2$28
Merck2$25
Impel Pharmaceuticals LLC1$21
Abbott1$20
Idorsia Pharmaceuticals US Inc1$16
Mallinckrodt Enterprises LLC1$15
Alfasigma USA, Inc.1$14
Shionogi Inc1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in New Jerseyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$556,050
Medicare patients
118
Services billed
19,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5011$430,471
UbrelvyUbrogepant71$104,348
QuliptaAtogepant36$39,582
AptiomEslicarbazepine Acetate14$34,971
Nurtec OdtRimegepant Sulfate21$31,239
OzempicSemaglutide20$22,318
BotoxOnabotulinumtoxina15$19,847
XcopriCenobamate13$15,076
Oxcarbazepine35$3,510
Memantine Hcl105$2,408
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine36$2,071
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen36$1,460
Donepezil Hcl144$1,217
Morphine Sulfate ErMorphine Sulfate22$1,041
Clobazam17$992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$70,880$163,777122 claims
Sunovion Pharmaceuticals Inc.Aptiom$140$34,97114 claims
PfizerNurtec Odt$1,084$31,23921 claims
SK Life Science, Inc.Xcopri$214$15,07613 claims
Upsher-smith Laboratories LLCTopiramate$114$31828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in New Jerseyon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Edgewater

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →